Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences (NYSE:RCUS) announced today that it will host an in-person and virtual Investor Event for analysts and investors on Monday, October 6, 2025, beginning at 10:00 AM ET, in New York City. The event will highlight new data for Arcus’s HIF-2a inhibitor casdatifan from the monotherapy cohorts of the Phase 1b ARC-20 trial in late-line clear cell renal cell carcinoma (ccRCC). Featured presenters will include members of the Arcus management team and key opinion leaders with expertise in HIF-2a biology and treatment of ccRCC. Lastly, Arcus will also discuss its extensive research efforts and advanced preclinical programs against autoimmune and inflammatory diseases, likely to deliver new Investigational New Drug filings in 2026 and 2027. Please contact Arcus Investor Relations regarding in-person attendance. A live webcast of the Investor Event will be available in the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com . A replay will be available following the live event. About Arcus Biosciences Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including domvanalimab, an Fc-silent anti-TIGIT antibody being studied in combination with zimberelimab, an anti-PD-1 antibody, for upper gastrointestinal and non-small cell lung cancer, casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com . Investor Inquiries Pia Eaves (Banerjee) Head of Investor Relations & Strategy (617) 459-2006 [email protected] Media Inquiries Holli Kolkey VP of Corporate Communications (650) 922-1269 [email protected] Maryam Bassiri AD, Corporate Communications (510) 406-8520 [email protected] Source: Arcus Biosciences Investor Contact [email protected] Investor Email Alerts To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time. * Required Email Address * Mailing Lists * Press Releases Events SEC Filings EOD Stock Quote Email Alert Sign Up Confirmation Explore More Read our latest press releases and announcements Browse Join forces with us on our mission to defeat cancer Connect Arcus clinical trials are currently enrolling Sign up Arcus Biosciences is a registered trademark of Arcus Biosciences, Inc. © Arcus Biosciences, Inc. All rights reserved. 3928 Point Eden Way, Hayward, CA 94545 About Us Our Science Editorials Careers Investors & Media Contact Terms of Use Sitemap Privacy Policy Washington Health Data Privacy Policy Cookie Policy DO NOT SELL/SHARE MY PERSONAL INFORMATION Powered By Q4 Inc. 5.187.1.9 (opens in new window)

The release as fetched from its publisher. arcusbio.com ↗